Brief: Design Therapeutics Announces Four-Week IV Data From The RESTORE-FA Trial Of DT-216P2 Demonstrating Clinical Improvements And Comprehensive Biomarker Activity In Friedreich Ataxia
18/05/2026 12:04
May 18 (Reuters) - Design Therapeutics Inc DSGN.O: DESIGN THERAPEUTICS ANNOUNCES FOUR-WEEK IV DATA FROM THE RESTORE-FA TRIAL OF DT-216P2 DEMONSTRATING CLINICAL IMPROVEMENTS AND COMPREHENSIVE BIOMARKER ACTIVITY IN FRIEDREICH ATAXIA DESIGN THERAPEUTICS INC - DT-216P2 GENERALLY WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED DESIGN THERAPEUTICS INC - DT-216P2 IMPROVES PATIENT-REPORTED FATIGUE BY OVER FIVE POINTS AFTER FOUR WEEKS DESIGN THERAPEUTICS INC - TO PURSUE REGISTRATIONAL DEVELOPMENT FOR DT-216P2, UPDATE IN Q4 2026 DESIGN THERAPEUTICS INC - DT-216P2 AT 1 MPK IMPROVES M-FARS BY 6.4 POINTS AND UPRIGHT STABILITY BY 2.7 POINTS Source text: ID:nGNX341dL2 Further company coverage: DSGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Design Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Eli Lilly, BlackRock TCP Capital, Boston Scientific
Design Therapeutics falls after early-stage data for genetic disorder treatment
Brief: Design Therapeutics Announces Four-Week IV Data From The RESTORE-FA Trial Of DT-216P2 Demonstrating Clinical Improvements And Comprehensive Biomarker Activity In Friedreich Ataxia
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings
Design Therapeutics Q1 net loss narrows, beats analyst estimates